Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.

Abstract:

:In a double-blind study, 128 patients with essential hypertension, refractory to beta-blocker monotherapy, were randomised to 1 of 4 treatment groups. Felodipine 2.5 mg twice daily, 5mg twice daily, 10mg twice daily or matched placebo twice daily were administered in addition to the beta-blocker for 4 weeks. Mean supine blood pressure before randomisation to treatment was 167/104 +/- 20/7mm Hg. After 4 weeks of treatment, supine blood pressures 2 hours after dose were 161/98 +/- 20/10mm Hg (P), 152/92 +/- 23/8mm Hg (felodipine 2.5mg), 142/87 +/- 18/7mm Hg (felodipine 5mg) and 142/86 +/- 17/7mm Hg (felodipine 10mg). The falls in systolic and diastolic blood pressures were significantly greater for all 3 felodipine groups than for placebo. Blood pressure reductions were less marked 14 hours after dosage: 161/100 +/- 20/9mm Hg (P), 160/97 +/- 24/9mm Hg (felodipine 2.5mg), 153/97 +/- 21/11mm Hg (felodipine 5mg), and 157/94 +/- 19/9mm Hg (felodipine 10mg); but the two higher doses of felodipine produced a significantly greater sustained fall in blood pressure than placebo. There was a correlation between the dose of felodipine and its antihypertensive effect. Standing blood pressures were reduced to the same extent as supine measurements. Heart rate was not significantly affected. Bodyweight did not increase during the study. Side effects of felodipine therapy were minor, and mostly attributable to the vasodilatory properties of the drug. Only 4 patients withdrew because of side effects. It is concluded that felodipine is an effective and well tolerated antihypertensive drug, and that 5mg twice daily is a suitable starting dose in hypertensive patients refractory to beta-blocker monotherapy. It may be necessary to increase this dose to 10mg twice daily in selected patients.

journal_name

Drugs

journal_title

Drugs

authors

Sluiter HE

doi

10.2165/00003495-198700343-00023

subject

Has Abstract

pub_date

1987-01-01 00:00:00

pages

97-106

eissn

0012-6667

issn

1179-1950

journal_volume

34 Suppl 3

pub_type

临床试验,杂志文章,随机对照试验

相关文献

DRUGS文献大全
  • Rilpivirine.

    abstract::Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. The randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials in antiretroviral-naive adult patients with HIV-...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208590-000000000-00000

    authors: Sanford M

    更新日期:2012-03-05 00:00:00

  • Fetal pharmacotherapy.

    abstract::Rapid progress has recently been encountered in pharmacologically treating the unborn baby. This unique area of drug therapy raises new methodological and ethical questions. This article is a systematic review of known modalities of fetal pharmacotherapy, and aims to highlight essential principles, difficulties and co...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262050-00004

    authors: Koren G,Klinger G,Ohlsson A

    更新日期:2002-01-01 00:00:00

  • Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.

    abstract::A once-daily preservative-free fixed combination ophthalmic solution containing tafluprost 0.0015 % and timolol 0.5 % (hereafter referred to as tafluprost/timolol) [Taptiqom(®)] has been developed to lower intraocular pressure (IOP) whilst avoiding damage to the ocular surface associated with preservatives such as ben...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0476-9

    authors: Hoy SM

    更新日期:2015-10-01 00:00:00

  • Effect of a single dose of cefotaxime or ceftriaxone on human faecal flora. A double-blind study.

    abstract::The effect of cefotaxime and ceftriaxone on faecal flora was investigated in women undergoing routine vaginal or abdominal hysterectomy. Three groups of 9 patients received, in a double-blind fashion and just before surgery, cefotaxime 2g intravenously, ceftriaxone 2g intravenously or no antibiotic (controls). Stools ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198800352-00004

    authors: Michéa-Hamzehpour M,Auckenthaler R,Kunz J,Pechère JC

    更新日期:1988-01-01 00:00:00

  • Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.

    abstract::Immunotherapies have shown remarkable success in the treatment of multiple cancer types; however, despite encouraging preclinical activity, registration trials of immunotherapy in prostate cancer have largely been unsuccessful. Sipuleucel-T remains the only approved immunotherapy for the treatment of asymptomatic or m...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01456-z

    authors: Rathi N,McFarland TR,Nussenzveig R,Agarwal N,Swami U

    更新日期:2020-12-28 00:00:00

  • Correction to: Deprescribing Opioids in Chronic Non‑cancer Pain: Systematic Review of Randomised Trials.

    abstract::Page 9, Fig. 2, which originally appeared as. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01416-7

    authors: Mathieson S,Maher CG,Ferreira GE,Hamilton M,Jansen J,McLachlan AJ,Underwood M,Lin CC

    更新日期:2020-10-01 00:00:00

  • Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::Flecainide is a Class I antiarrhythmic drug of the local anaesthetic type. It can be given either intravenously or orally and its pharmacokinetic properties allow relatively long (12 hours) dosing intervals with oral administration. In several open and a few controlled therapeutic trials, orally administered flecainid...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198529010-00001

    authors: Holmes B,Heel RC

    更新日期:1985-01-01 00:00:00

  • Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases.

    abstract::Buflomedil hydrochloride is a vasoactive drug with a variety of pharmacodynamic properties. Importantly, it seems to improve nutritional blood flow in ischaemic tissue of patients with peripheral and/or cerebral vascular disease by a combination of pharmacological effects: inhibition of alpha-adrenoceptors, inhibition...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198733050-00002

    authors: Clissold SP,Lynch S,Sorkin EM

    更新日期:1987-05-01 00:00:00

  • Nivolumab: a review of its use in patients with malignant melanoma.

    abstract::Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0234-4

    authors: Deeks ED

    更新日期:2014-07-01 00:00:00

  • Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

    abstract:UNLABELLED:Oral delayed-release mesalazine is an enteric-coated formulation which releases mesalazine in the terminal ileum and colon. Up to 74% of patients with mild to moderately active ulcerative colitis experience endoscopic or symptomatic improvement (including remission) or both when treated with oral delayed-rel...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957030-00013

    authors: Prakash A,Markham A

    更新日期:1999-03-01 00:00:00

  • Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

    abstract::The original article can be found online. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01407-8

    authors: Scott LJ

    更新日期:2020-09-01 00:00:00

  • Inhibiting costimulatory activation of T cells : a viable treatment option for rheumatoid arthritis?

    abstract::There is now good evidence that T cells play a central role in the inflammatory pathway that leads to the persistent synovitis that causes joint damage in rheumatoid arthritis (RA). T cells require two signals to become activated. The second step in the activation of T cells involves costimulatory pathways, the best d...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767010-00001

    authors: Pollard LC

    更新日期:2007-01-01 00:00:00

  • Pharmacotherapy for hepatic encephalopathy.

    abstract::Hepatic encephalopathy (HE) is a challenging clinical complication of liver dysfunction with a wide spectrum of neuropsychiatric abnormalities that range from mild disturbances in cognitive function and consciousness to coma and death. The pathogenesis of HE in cirrhosis is complex and multifactorial, but a key role i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/10898630-000000000-00000

    authors: Phongsamran PV,Kim JW,Cupo Abbott J,Rosenblatt A

    更新日期:2010-06-18 00:00:00

  • Pharmacology and therapeutic use of calcitonin.

    abstract::Calcitonin is a peptide hormone secreted by the C-cells of the thyroid gland. A major physiological function of the hormone appears to be the protection of the skeleton against resorption in humans. It thus opposes the resorptive actions of parathyroid hormone and 1,25 dihydroxyvitamin D. This action is utilised pharm...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198121040-00002

    authors: Stevenson JC,Evans IM

    更新日期:1981-04-01 00:00:00

  • Clascoterone: First Approval.

    abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01417-6

    authors: Dhillon S

    更新日期:2020-11-01 00:00:00

  • Corticosteroids and adrenal suppression. Characterising and avoiding the problem.

    abstract::Glucocorticoids are used for a variety of illnesses. One of their major complications is suppression of the hypothalamic-pituitary-adrenal axis, rendering a patient unable to respond to stress. The risk of this suppression may be minimised by the use of short-acting glucocorticoid preparations, administration of the e...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198938050-00008

    authors: Helfer EL,Rose LI

    更新日期:1989-11-01 00:00:00

  • Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.

    abstract::Utilising a modified fixed-dose, 4 x 3 factorial design, the antihypertensive effects of all combinations of 4 doses of pinacidil (0, 12.5, 25 and 37.5 mg bid) with 3 doses of hydrochlorothiazide (0, 12.5 and 25 mg bid) were studied in patients with supine diastolic blood pressure of 95 to 110mm Hg. The decreases in s...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800367-00015

    authors: Goldberg MR,Offen WW

    更新日期:1988-01-01 00:00:00

  • A comparison of nimesulide and paracetamol in the treatment of fever due to inflammatory diseases of the upper respiratory tract in children.

    abstract::The efficacy and tolerability of nimesulide were compared with those of paracetamol in a nonblind randomised study that recruited 110 children (64 males, 46 females; aged 3 to 6 years) with inflammation of the upper respiratory tract and fever. Nimesulide suspension (1.5 mg/kg 3 times daily) or paracetamol syrup (10 m...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199300461-00059

    authors: Polidori G,Titti G,Pieragostini P,Comito A,Scaricabarozzi I

    更新日期:1993-01-01 00:00:00

  • Liposomal drug formulations. Rationale for development and what we can expect for the future.

    abstract::Liposomes are versatile drug carriers which can be used to solve problems of drug solubility, instability and rapid degradation. Both hydrophilic and hydrophobic drugs can be associated with liposomes and special techniques have been developed for the efficient loading of weak acids and weak bases into liposomes. Lipo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856050-00001

    authors: Allen TM

    更新日期:1998-11-01 00:00:00

  • White coat hypertension and related phenomena. A clinical approach.

    abstract::In this paper, several clinical problems associated with the diagnosis of hypertension are discussed. Blood pressure variability and reactivity are factors underlying the difficulties in the diagnosis of hypertension. These phenomena are interrelated and mixed. White coat hypertension (WCH), referring to the phenomeno...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300462-00017

    authors: Ocón-Pujadas J,Mora-Maciá J

    更新日期:1993-01-01 00:00:00

  • Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

    abstract:UNLABELLED:Patients with beta-thalassaemia and other transfusion-dependent diseases develop iron overload from chronic blood transfusions and require regular iron chelation to prevent potentially fatal iron-related complications. The only iron chelator currently widely available is deferoxamine, which is expensive and ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958030-00021

    authors: Barman Balfour JA,Foster RH

    更新日期:1999-09-01 00:00:00

  • Tofacitinib: A Review in Rheumatoid Arthritis.

    abstract::Tofacitinib (Xeljanz®) is a potent, selective JAK inhibitor that preferentially inhibits Janus kinase (JAK) 1 and JAK3. In the EU, oral tofacitinib 5 mg twice daily is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are int...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0835-9

    authors: Dhillon S

    更新日期:2017-12-01 00:00:00

  • Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.

    abstract::The development of chronic heart failure (CHF) includes phenotypic changes in a host of homeostatic systems so that, as the disease advances, CHF may be seen as a multi-system disorder with its origins in the heart but embracing many extra-cardiac manifestations. Immunological abnormalities are recognised in this cont...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060060-00002

    authors: Bolger AP,Anker SD

    更新日期:2000-12-01 00:00:00

  • Desloratadine.

    abstract::Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine. The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers. Therapeutic dosages had no effects on wakefulness or psycho...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200161060-00007

    authors: McClellan K,Jarvis B

    更新日期:2001-01-01 00:00:00

  • Aggravation of ventricular arrhythmia. A drug-induced complication.

    abstract::Each antiarrhythmic agent can cause side effects, but most of these are easily recognised by the patient or physician. However, one potentially serious side effect common to all of these drugs is aggravation of ventricular arrhythmia. Often this is without symptoms and goes unrecognised by the patient. It occurs in 11...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500294-00009

    authors: Podrid PJ

    更新日期:1985-01-01 00:00:00

  • Susoctocog Alfa: A Review in Acquired Haemophilia A.

    abstract::Intravenous susoctocog alfa (Obizur(®)) is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). Intravenous susoctocog alfa was an effective and generally well to...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0576-1

    authors: Burness CB,Scott LJ

    更新日期:2016-05-01 00:00:00

  • Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.

    abstract::Chenodeoxycholic acid (chenic acid; CDCA) is 1 of the 3 major biliary bile acids in man. When administered in pharmacological doses it causes a decrease in cholesterol saturation of bile, which in turn may lead to gradual dissolution of cholesterol gallstones. The stone dissolution rate during CDCA therapy has varied ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198121020-00002

    authors: Iser JH,Sali A

    更新日期:1981-02-01 00:00:00

  • Herb-drug interactions: a literature review.

    abstract::Herbs are often administered in combination with therapeutic drugs, raising the potential of herb-drug interactions. An extensive review of the literature identified reported herb-drug interactions with clinical significance, many of which are from case reports and limited clinical observations. Cases have been publis...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565090-00005

    authors: Hu Z,Yang X,Ho PC,Chan SY,Heng PW,Chan E,Duan W,Koh HL,Zhou S

    更新日期:2005-01-01 00:00:00

  • Treatment of the chronic fatigue syndrome. A review and practical guide.

    abstract::The chronic fatigue syndrome (CFS) was formally defined in 1988 to describe a syndrome of severe and disabling fatigue of uncertain aetiology associated with a variable number of somatic and/or psychological symptoms. CFS has been reported in most industrialised countries and is most prevalent in women aged between 20...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199346040-00005

    authors: Blondel-Hill E,Shafran SD

    更新日期:1993-10-01 00:00:00

  • Current, new and future treatments in dyslipidaemia and atherosclerosis.

    abstract::The new therapeutic options available to clinicians treating dyslipidaemia in the last decade have enabled effective treatment for many patients. The development of the HMG-CoA reductase inhibitors (statins) have been a major advance in that they possess multiple pharmacological effects (pleiotropic effects) resulting...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060010-00005

    authors: Chong PH,Bachenheimer BS

    更新日期:2000-07-01 00:00:00